Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2013-11-18 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a positive scientific advice meeting and marketing application strategy for a drug. The document is short (2195 characters) and primarily serves as a regulatory update with an attached press release. It does not contain detailed financial statements, management discussion, or comprehensive report data. According to the rules, Form 6-K filings are periodic regulatory filings for foreign issuers and typically fall under Regulatory Filings (RNS) unless they contain full financial reports or other specific report types. This document is a regulatory announcement and does not meet criteria for other categories like Annual Report, Interim Report, or Earnings Release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2013-11-18 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release reporting third quarter 2013 results and interim unaudited financial information for the nine months ended September 30, 2013. Form 6-K filings are typically used by foreign private issuers to provide interim or periodic reports similar to quarterly or interim reports. The presence of interim unaudited financial information and quarterly results indicates this is an Interim / Quarterly Report. The document length is 1892 characters, which is short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2013-11-12 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer pursuant to SEC rules. It includes a press release about a presentation at a conference but does not contain financial statements or detailed financial data. The document length is short (2158 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, such filings that are announcements or brief reports without substantive financial data fall under Regulatory Filings (RNS).
2013-10-31 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about initiating a Phase III study for a drug. Form 6-K filings are periodic reports submitted by foreign private issuers to provide information that is material to investors but are not annual or quarterly reports. The document is short (2141 characters) and primarily serves as a regulatory announcement of a press release rather than a full financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2013-10-30 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a presentation at a conference, but does not contain detailed financial statements or substantive financial data. The document length is short (2132 characters), and it primarily serves as a regulatory update rather than a full report. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2013-10-23 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release about FDA acceptance of an IND application for a Phase III study. The document is short (2187 characters) and primarily serves as a regulatory announcement rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2013-10-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.